Le Lézard
Classified in: Health
Subject: SVY

Wilson's Disease Epiomic Epidemiology Forecast 2018-2028


DUBLIN, Sept. 19, 2018 /PRNewswire/ --

The "Epiomic Epidemiology Series: Wilson's Disease Forecast In 28 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Wilson's disease, also known as progressive lenticular degeneration, is a genetic disorder inherited in an autosomal recessive manner. It is caused by mutations in a gene coding for a copper-transporting protein with a key role in copper metabolism. Reduced activity of the protein leads to copper accumulation in the body which results in various hepatic, osseous, neurological and psychiatric manifestations. Although the genotype-phenotype correlation is still to be elucidated, therapies that are currently available permit patients to live fairly normal lives. However, hepatic and neurological damage sustained prior to the commencement of therapy can be irreversible.

This report provides the current prevalent population for Wilson's disease across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Bulgaria, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the publisher's analysis team, Wilson's disease patients grouped by genetic features, various symptoms and treatments have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of Wilson's disease include:

Key Topics Covered:

  1. List Of Tables And Figures
  2. Introduction
  3. Cause Of The Disease
  4. Risk Factors & Prevention
  5. Diagnosis Of The Disease
  6. Variation By Geography/Ethnicity
  7. Disease Prognosis & Clinical Course
  8. Key Comorbid Conditions / Features Associated With The Disease
  9. Methodology For Quantification Of Patient Numbers
  10. Top-Line Prevalence For Wilson'S Disease
  11. Features Of Wilson'S Disease Patients
  12. Signs And Symptoms Of Wilson'S Disease Patients
  13. Hepatic Signs And Symptoms
  14. Neurological Signs And Symptoms
  15. Psychological Signs And Symptoms
  16. Ophthalmologic Signs And Symptoms
  17. Treatment Of Wilson'S Disease Patients
  18. Abbreviations Used In The Report
  19. Other Publisher Services & Solutions
  20. Reports & Publications
  21. Online Epidemiology Databases
  22. Online Pharmaceutical Pricing Database
  23. References
  24. Appendix

For more information about this report visit

https://www.researchandmarkets.com/research/8phsm2/wilsons_disease?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 06:00
The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in...

at 06:00
65,000 Ontario hospital workers represented by the Ontario Council of Hospital Unions-CUPE (OCHU-CUPE) and SEIU Healthcare will see a 6% wage increase (3% wage increases in each of the next two years), improvements to health and dental benefits,...

at 05:29
SmartCella Holding AB today announces that Dr Ricardo Baptista has been appointed Chief Technology Officer (CTO) and Head of Procella. Ricardo is an experienced Biochemical Engineer with almost 20-years of global experience in the medical...

at 05:15
Every year in Quebec, more than 2,000 young people leave the care of the Director of Youth Protection (DYP) as they approach the age of majority. For youth under the care of the DYP, turning 18 means having to become independent quickly, with little...

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...



News published on and distributed by: